Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Jaffe

Showing results (471-480 of 579) with videos related to

Pageof 58
Sort By:
Investigative Ophthalmology & Visual Science|April 26, 2020
Resveratrol Protects Against Hydroquinone-Induced Oxidative Threat in Retinal Pigment Epithelial CellsSamantha E Neal, Kristen L Buehne, Nicholas A Besley, et al.
Ophthalmology|January 20, 2016
Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments TrialsSumit Sharma, Cynthia A Toth, Ebenezer Daniel, et al.
Ophthalmology|May 5, 2012
Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results, Daniel F Martin, Maureen G Maguire, et al.
The British Journal of Ophthalmology|January 13, 2016
Wide field of view swept-source optical coherence tomography for peripheral retinal diseaseRyan P McNabb, Dilraj S Grewal, Rajvi Mehta, et al.
Ophthalmology|March 24, 2020
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration: Two-Year Results, , Daniel F Martin, et al.
Ophthalmology|September 19, 2015
Association of Baseline Characteristics and Early Vision Response with 2-Year Vision Outcomes in the Comparison of AMD Treatments Trials (CATT)Gui-shuang Ying, Maureen G Maguire, Ebenezer Daniel, et al.
Ophthalmology. Retina|June 26, 2018
Baseline Predictors for Five-Year Visual Acuity Outcomes in the Comparison of AMD Treatment TrialsGui-Shuang Ying, Maureen G Maguire, Wei Pan, et al.
Ophthalmology|June 24, 2020
HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular DegenerationPravin U Dugel, Rishi P Singh, Adrian Koh, et al.
Ophthalmology|October 3, 2021
ReplyGlenn J Jaffe, Keith Westby, Karl G Csaky, et al.
Ophthalmology Science|October 17, 2022
Phase 1 Study of THR-687, a Novel, Highly Potent Integrin Antagonist for the Treatment of Diabetic Macular EdemaArshad M Khanani, Sunil S Patel, Victor H Gonzalez, et al.
Pageof 58

Showing results (471-480 of 579) with videos related to

Sort By:
Pageof 58
Investigative Ophthalmology & Visual Science|April 26, 2020
Resveratrol Protects Against Hydroquinone-Induced Oxidative Threat in Retinal Pigment Epithelial CellsSamantha E Neal, Kristen L Buehne, Nicholas A Besley, et al.
Ophthalmology|January 20, 2016
Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments TrialsSumit Sharma, Cynthia A Toth, Ebenezer Daniel, et al.
Ophthalmology|May 5, 2012
Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results, Daniel F Martin, Maureen G Maguire, et al.
The British Journal of Ophthalmology|January 13, 2016
Wide field of view swept-source optical coherence tomography for peripheral retinal diseaseRyan P McNabb, Dilraj S Grewal, Rajvi Mehta, et al.
Ophthalmology|March 24, 2020
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration: Two-Year Results, , Daniel F Martin, et al.
Ophthalmology|September 19, 2015
Association of Baseline Characteristics and Early Vision Response with 2-Year Vision Outcomes in the Comparison of AMD Treatments Trials (CATT)Gui-shuang Ying, Maureen G Maguire, Ebenezer Daniel, et al.
Ophthalmology. Retina|June 26, 2018
Baseline Predictors for Five-Year Visual Acuity Outcomes in the Comparison of AMD Treatment TrialsGui-Shuang Ying, Maureen G Maguire, Wei Pan, et al.
Ophthalmology|June 24, 2020
HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular DegenerationPravin U Dugel, Rishi P Singh, Adrian Koh, et al.
Ophthalmology|October 3, 2021
ReplyGlenn J Jaffe, Keith Westby, Karl G Csaky, et al.
Ophthalmology Science|October 17, 2022
Phase 1 Study of THR-687, a Novel, Highly Potent Integrin Antagonist for the Treatment of Diabetic Macular EdemaArshad M Khanani, Sunil S Patel, Victor H Gonzalez, et al.
Pageof 58